<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00142974</url>
  </required_header>
  <id_info>
    <org_study_id>CHTF919G2203</org_study_id>
    <nct_id>NCT00142974</nct_id>
  </id_info>
  <brief_title>Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy</brief_title>
  <official_title>Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the safety, tolerability and satisfactory relief of
      tegaserod against dyspeptic symptoms in diabetic patients with symptoms of diabetic
      gastropathy.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was terminated early in April 2005 due to low patient enrollment
  </why_stopped>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in weekly mean of a daily composite diabetic gastropathy dyspeptic symptom severity score throughout 6 weeks of treatment.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weekly global measure of dyspeptic symptom relief.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weekly mean severity of individual dyspeptic symptoms (nausea, vomiting, retching, epigastric/stomach, discomfort/pain, postprandial fullness, bloating, early satiety).</measure>
  </secondary_outcome>
  <enrollment>120</enrollment>
  <condition>Diabetic Gastropathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegaserod</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of Type 1 or insulin-requiring Type 2 diabetes for at least 3 years

          -  GI symptoms for at least 2 months before entering study

        Exclusion Criteria:

          -  Very high body weight

          -  Significant diarrhea

          -  Ulcers

        Symptom severity score collected via diary Other protocol-defined inclusion/exclusion
        criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis</last_name>
    <role>Study Chair</role>
    <affiliation>Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis</name>
      <address>
        <city>Basel</city>
        <zip>4056</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2005</study_first_submitted>
  <study_first_submitted_qc>August 31, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>April 19, 2012</last_update_submitted>
  <last_update_submitted_qc>April 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes, tegaserod, gastropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegaserod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

